Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Toujiequwen Granules
- Development stage
- Unknown
- Lead developer
- E-Fong Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Toujiequwen Granules, originally known as the Pneumonia No. 1 Formula (肺炎1号方), is a Traditional Chinese Medicine (TCM) product developed by the Guangzhou Eighth People's Hospital for the treatment of mild to moderate COVID-19. The formulation was granted emergency approval for hospital use by the Guangdong Provincial Medical Products Administration in February 2020. It consists of 16 herbal ingredients, including Forsythiae Fructus (Lianqiao) and Lonicerae Japonicae Flos (Jinyinhua), which are traditionally used to clear heat and detoxify. Clinical observations and retrospective studies have indicated that the granules can improve clinical symptoms such as fever and cough, and may reduce the likelihood of patients progressing to severe disease. The production of the granules was scaled up through a partnership with Zhongsheng Pharmaceutical to meet demand during the pandemic.
- Brand names
- Toujiequwen Granules
- Other names
- Tou-Jie-Qu-Wen Granules透解祛瘟颗粒Pneumonia No. 1 Formula
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on Toujiequwen Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Toujiequwen Granules.